Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-NY-ESO-1 TCR/CD8alpha-expressing T cells GSK3901961

A preparation of human autologous T lymphocytes that are genetically modified to express a T-cell receptor (TCR) specific for the human cancer-testis antigen NY-ESO-1 and the CD8alpha co-receptor, with potential immunostimulating and antineoplastic activities. Upon leukapheresis, isolation, transduction, expansion ex vivo, and reintroduction into the patient, the autologous anti-NY-ESO-1 TCR/CD8alpha-expressing T cells GSK3901961 recognize and bind to NY-ESO-1-overexpressing tumor cells. This may result in a specific cytotoxic T-lymphocyte (CTL)-mediated killing of NY-ESO-1-positive tumor cells. NY-ESO-1, a tumor-associated antigen (TAA), is found in normal testis and on the surface of various tumor cell types. Co-expression of CD8alpha may broaden the immune response against tumors and increase antitumor activity by converting CD4+ helper T cells into CD8+ cytotoxic T cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-NY-ESO-1 TCR/CD8a-expressing T cells GSK3901961
Code name:GSK 3901961
GSK-3901961
GSK3901961
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search